- Home
- QTWO vs NAMS Comparison
QTWO vs NAMS Comparison
Compare QTWO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTWO | NAMS |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | QTWO | NAMS |
|---|---|---|
| Price | $50.14 | $30.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $86.25 | $46.75 |
| AVG Volume (30 Days) | ★ 1.4M | 809.4K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $193,978,000.00 | N/A |
| Revenue This Year | $12.48 | $25.64 |
| Revenue Next Year | $10.18 | $530.85 |
| P/E Ratio | $63.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.16 | $14.06 |
| 52 Week High | $95.10 | $42.00 |
Technical Indicators
Market Signals| Indicator | QTWO | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 38.16 |
| Support Level | $46.16 | $23.48 |
| Resistance Level | $75.62 | $37.43 |
| Average True Range (ATR) | 2.13 | 1.75 |
| MACD | 0.71 | -0.36 |
| Stochastic Oscillator | 54.56 | 14.78 |
Price Performance
Historical ComparisonAbout QTWO Q2 Holdings Inc.
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.